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Hypertension is one of the most important causes of cardiovascular and renal 
morbidity and mortality, and it represents a serious health problem in Western 
countries. Over the last few decades scientific interest on food-derived 
antihypertensive peptides has grown as an alternative to drugs in the control of 
systemic blood pressure. Most of these peptides target the angiotensin I-
converting enzyme (ACE) but emerging evidence points to other antihypertensive 
mechanisms beyond ACE inhibition. The milk protein lactoferrin (LF) is a good 
source of orally active antihypertensive peptides the characterization of which, 
including ex vivo functional assays and in vivo approaches, shows that they might 
act on several molecular targets. This review summarizes the mechanisms of 
action underlying the blood pressure-lowering effects of LF-derived peptides, 
focusing on their interaction with different components of the renin-angiotensin 
(RAS) and endothelin (ET) systems. The ability of LF-derived peptides to modify 
the expression of genes encoding proteins involved in the nitric oxide (NO) 
pathway and prostaglandin synthesis is also described.  
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1. Introduction  
During the last two decades, it has been recognized that apart from their basic 
nutritional role, many dietary proteins contain within their primary structure 
different peptide sequences that exert beneficial effects upon human health once 
released by food processing or by digestive enzymes during gastrointestinal 
transit. These bioactive peptides range in size from 2 to 50 amino acid residues 
and exhibit different activities, based on their inherent amino acid composition 
and sequence.1-3 Moreover, some of these peptides are multifunctional, which is 
very attractive for dietary approaches and for functional food development. 
Due to the prevalence and importance of hypertension in the Western 
population, scientific interest on antihypertensive peptides has grown as an 
alternative to drugs in the control of systemic blood pressure (BP) and prevention 
of associated cardiovascular disease (CVD) events.4-6 The main target for 
antihypertensive food-derived peptides is the angiotensin I-converting enzyme 
(ACE), which in vitro inhibition is well established. However, the in vivo
mechanism underlying vasoactive and BP-lowering effects of antihypertensive 
food-derived peptides has not yet been fully established and emerging evidence 
points to other antihypertensive mechanisms beyond ACE inhibition.7-9
The milk protein lactoferrin (LF), which possesses a diverse range of 
physiological functions such as antimicrobial/antiviral, immunomodulatory and 
antioxidant activities,10-12 was a decade ago pointed out by in silico studies as a 
promising source of ACE-inhibitory peptides.13 Since then, our group focused on 
the characterization of the antihypertensive effects of LF-derived peptides using 
different experimental approaches and models. In this review, first we briefly 
describe the importance of hypertension, the physiological control of BP and the 
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potential role of milk protein-derived peptides in hypertension management. Then 
the paper focuses on the scientific knowledge about the BP-lowering effects of 
LF-derived peptides and hydrolysates and the mechanisms underlying their 
antihypertensive effects, which seem not only limited to ACE inhibition. 
2. Hypertension 
Hypertension, or raised BP, is defined as a systolic BP (SBP) equal to or above 
140 mm Hg and/or diastolic BP (DBP) equal to or above 90 mm Hg. Hypertension 
is responsible for at least 45% of deaths due to heart disease, and 51% of deaths 
due to stroke. Globally CVD accounts for approximately 17 million deaths a year, 
nearly one third of the total. Out of these, complications of hypertension account 
for 9.4 million deaths worldwide every year.14 Overall the prevalence of 
hypertension appears to be around 3045% of the general population, with a 
steep increase with ageing.15 Therefore, arterial hypertension is a serious health 
problem in developed and developing countries, also from an economic point of 
view since it causes an elevated cost for governments. It has been estimated 
that, at population level, a reduction in SBP of only 2 mm Hg would result in a 6% 
reduction in fatal stroke, and a 4% reduction in fatal coronary heart disesase.16
2.1. Physiological control of blood pressure 
Normal levels of both SBP (120 mm Hg) and DBP (80 mm Hg) are particularly 
important for the efficient function of vital organs such as the heart, brain and 
kidneys and for overall health and wellbeing. Short- and long-term control of BP 
is accomplished by a number of different interacting mechanisms. Short-term 
control occurs primarily through the effects of the autonomic nervous system on 
5 
total peripheral vascular resistance and capacitance, and on cardiac pumping 
ability. Long-term control is performed by multiple nervous and hormonal 
controls, and by local control systems within the kidneys that regulate their 
excretion of salt and water.17 Among them, the renin-angiotensin system (RAS), 
kallikrein-kinin system, the endothelin (ET) system and the natriuretic peptide 
(NP) system have been associated with long-term BP control. These systems 
generate a variety of vaso-regulatory peptides that collectively modulate BP, and 
also fluid and electrolyte balance, via membrane bound receptors located on 
different tissues. Hence, the main components of these systems are the targets 
for hypertension drug treatments and also for food-derived bioactive peptides. 
The RAS pathway is one of the main targets for the treatment of 
hypertension, and its inhibition at three possible levels, ACE, upstream renin 
activity or downstream angiotensin type 1 (AT1) receptors is the pharmacological 
basis for commonly used antihypertensive drugs.18 The kallikrein-kinin system 
represents a metabolic cascade that triggers the release of vasoactive kinins, 
among which the vasodilatory nonapeptide bradykinin is known best.19 Figure 1 
shows the components and functional steps by which the RAS and kallikrein-kinin 
system help to regulate arterial pressure.20 As can be seen both systems are 
connected by ACE which degrades angiotensin I (Ang I) and bradykinin.  
Another peptidic system, the ET system, has also an increasingly 
recognized role in BP regulation, and has also been targeted for hypertension 
drug treatment.21 The synthesis of ET parallels that of the previously described 
peptide systems in that a precursor polypeptide, preproendothelin (preproET-1) 
is sequentially cleaved to generate the active form, ET-1 which has powerful 
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vasoconstrictor and pressor properties.22 Figure 2 shows the regulation of blood 
pressure through the ET system. 
The NP system consists primarily of three well-characterized peptides 
atrial NP (ANP), B-type NP (BNP) and C-type NP (CNP). The biological effects 
of these three peptides include among others natriuresis, vasodilatation and 
inhibition of the RAS. The NPs are cleared from the circulation via enzymatic 
degradation by neutral endopeptidase (NEP), a zinc-dependent membrane 
bound endopeptidase which is also critical for the processing and catabolism of 
Ang I, bradykinin and ET-1. Since many substrates for NEP are peptides with 
vasoactive and diuretic/natriuretic actions, NEP inhibitors have been examined 
as a potential therapeutic modality for hypertension treatment.23
2.2. Lifestyle interventions for hypertension management 
The prevention of arterial hypertension development through the diet has 
received increasing interest, and several studies support a valid association of a 
limited number of dietary factors and dietary patterns with CVDs.24 A diet low in 
saturated and total fat and rich in fruit, vegetables and low-fat dairy products 
substantially lowered BP in the Dietary Approaches to Stop Hypertension (DASH) 
Trial.25 More recently, interest has grown into macronutrients intake, including 
dietary protein.26 Several studies evidence a beneficial effect of protein intake on 
BP, specifically for plant and milk protein.27-29 However in some epidemiological 
studies no inverse relation between high protein intake and BP has been seen.30
The antihypertensive mechanism of protein is still unknown, but one possibility is 
the degradation of protein into peptides that have antihypertensive effects. In this 
context, an inverse association between low fat dairy intake and BP was found31, 
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32 and linked to bioactive peptides33, 34 . However dairy products also contain 
minerals such as calcium, potassium or magnesium, and vitamins that may 
individually or in combination reduce BP.35-38
3. Milk protein-derived antihypertensive peptides 
Milk proteins are the most important source of bioactive peptides, although 
other animal as well as plant proteins also contain potential bioactive sequences.2
The primary and secondary structures of major human and bovine milk proteins 
are well characterized and the potential bioactivities of peptides released from 
these proteins are currently a subject of intensive research worldwide. There is 
now a considerable amount of scientific data to demonstrate that a wide range of 
milk peptides can regulate specific physiological functions in experimental 
animals and humans.39-42 Undoubtedly, those with BP-lowering effects are 
receiving increasing attention as an alternative to drugs in the control of systemic 
BP and prevention of associated CVD events.4-6, 43 These peptides might interact 
with the main components of BP regulatory pathways, such as RAS, kallikrein-
kinin system, ET system and NP system, but nowadays ACE is the main target 
for antihypertensive milk-derived peptides developed as an alternative to drugs.6
The most extensively studied milk-derived antihypertensive peptides are 
the so-called lactotripeptides of sequences VPP and IPP, which can be obtained 
from casein by means of either milk fermentation44 or enzymatic hydrolysis using 
microbial proteases.45 In contrast to the published data from animal studies in 
which both lactotripeptides have shown clear antihypertensive effects in different 
hypertension models,46 human data are more contradictory. Significant 
decreases of 4.8 mm Hg in SBP and 2.2 mm Hg in DBP were found in a meta-
analysis which included 12 clinical trials,33 in accordance with a similar meta-
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analysis performed by Pripp.47 However, in further clinical trials several authors 
did not find any significant effect either on SBP or DBP by treatment with 
lactotripeptide-containing products.48-50 Finally, a recent meta-analysis of small 
doses of lactotripeptides on 19 randomized, placebo-controlled clinical 
intervention trials showed an overall BP lowering effect (-4.0 mm Hg for SBP; -
1.0 mm Hg for DBP), although a positive effect was not reported in all the 
studies.51 These contradictory data were reflected in a recent Scientific Opinion 
of the European Food Safety Authority on the substantiation of health claims 
related to IPP and VPP and maintenance of normal BP, which stated that there 
was no convincing evidence for a mechanism by which these widely studied 
bioactive peptides could exert the claimed effect.52
4. Lactoferrin and its derived bioactive peptides 
LF is an 80 kDa iron-binding glycoprotein of the transferrin family, which was first 
fractionated as an unknown red fraction from cows milk in 1939.53 Later on, the 
red protein from both human and bovine milk was defined as a transferrin-like 
glycoprotein.54, 55 In mammals, LF is present in milk as a minor component of the 
whey fraction and also in other exocrine secretions and neutrophil granules. 
Nowadays it has become evident that oral administration of LF exerts several 
beneficial effects on the health of humans and animals, including anti-infective, 
anticancer, and anti-inflammatory effects. With regard to the effects of LF on BP, 
it has been described that chronic administration of LF strongly reduced the BP 
and improved antioxidant capacity in a rat model of dexamethasone-induced 
hypertension, suggesting that the antioxidant effect might play a role in the 
antihypertensive action of LF.56 Moreover LF has an endothelial NO-dependent 
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hypotensive effect in rats, which is also possibly mediated by the central 
opioidergic system.57 Basic research and technological aspects of the application 
of LF have been extensively reviewed.10-12, 58, 59
With respect to LF-derived peptides, the most well-known is lactoferricin B 
(LfcinB) which can be released from bovine LF through proteolysis by pepsin 
under acidic conditions,60 a reaction that occurs naturally in the stomach.61, 62
LfcinB is a 25-amino acid cationic antimicrobial peptide with an amphipathic, 
antiparallel -sheet structure.63 It has a single disulfide bond and no iron-binding 
capacity. Interestingly, LfcinB not only retains but improves the activities of LF. 
LfcinB possesses strong antimicrobial64-67 and weak antiviral68, 69 activities and it 
also has potent antitumoral and immunological properties70. Moreover, shorter 
derivatives of LfcinB, which are devoid of the disulfide bond, also exhibit 
antimicrobial activity.71-75 Research on LfcinB and related peptides which are 
various short-length and amino acid-substituted peptides has been summarized 
in several comprehensive reviews.70, 76, 77
Despite the in silico analysis of Vermeirssen et al.13 where LF stood out as 
a promising source of ACE-inhibitory peptides and the multifunctionality showed 
by LfcinB and related sequences, no attempts had been done to characterize the 
potential antihypertensive effects of LF-derived peptides until the 
antihypertensive effect after intravenous injection in spontaneously hypertensive 
rats (SHR) of the ACE-inhibitory sequence LRPVAA was described.78 Later on, 
other LF-derived peptides with oral BP-lowering effects in SHR were reported. 
These studies include both short-term and long-term administration of potential 
antihypertensive peptides, and some of them include as well the effect of 
antihypertensive peptides on the SBP of the normotensive control WistarKyoto 
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(WKY) rat strain. Although initially characterized as in vitro ACE inhibitors, further 
studies including ex vivo functional assays and in vivo approaches showed that 
these peptides might act on several molecular targets as explained below. 
5. Mechanisms of action of lactoferrin-derived antihypertensive peptides 
5.1 Effects on the renin-angiotensin system 
5.1.1. ACE inhibition 
In vitro ACE inhibitory effects. ACE-inhibitory potency is expressed as the IC50
value, or concentration needed to inhibit 50% of ACE activity. Methods based on 
spectrophotometric or fluorimetric detection as well as high-performance liquid 
chromatography (HPLC) assays employing different peptide analogs as 
substrates have been described.5 Also the natural ACE substrates Ang I or 
bradykinin can be used to characterize ACE-inhibitory activity although 
differences depending on the substrate used in the in vitro determinations have 
been described.79
In vitro ACE-inhibitory sequences derived from different regions of the LF 
sequence, including its antimicrobial domain LfcinB, have been characterized 
(Table 1).80-82 The ACE-inhibitory potencies of LF-derived peptides varied over a 
300-fold range, with IC50 values of the same order of magnitude as those reported 
for ACE-inhibitory peptides derived from different milk proteins.4 The two most 
potent LF-derived peptides corresponded to sequences LIWKL (IC50 = 0.47 µM)82
and LRP (IC50 = 0.35 µM)80. Of note, their IC50 values are at least ten-fold lower 
than those described for the casein-derived antihypertensive tripeptides VPP 
(IC50 = 9.0 µM) and IPP (IC50 = 5.0 µM).83 Interestingly the short-term 
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antihypertensive effect of both LF-derived sequences in SHRs remained 
significant up to 24h post-administration.80, 82
Despite the pioneering studies about ACE-inhibitory peptides derived from 
snake venom and their structural analogues, which showed the importance of the 
C-terminal dipeptide hydrophobic sequences of ACE substrates and inhibitors,84-
86 the effect of primary structure on potency is not fully understood. Quantitative 
structure-activity modeling of ACE-inhibitory peptides derived from milk proteins 
has shown no relationship between N-terminal structure and inhibitory potency.87
By contrast, when we characterized LfcinB-derived peptides,81 the sequences 
LfcinB19-25, LfcinB18-25 and LfcinB17-25, derived from elongations at the N-terminal 
end of LfcinB20-25 showed higher in vitro potency than the parental one, 
suggesting a relationship between N-terminal sequence and inhibitory activity. 
The four above-mentioned peptides have positively-charged R as the C-terminal 
residue, which has been described to contribute substantially to ACE inhibitory 
potency in casein-derived peptides,88 although it does not fit with the rule 
proposed about residues being preferred in ultimate position (W, Y, F, P, I, A, L, 
M) of ACE inhibitors and substrates.85
The different ACE inhibitory potency found between LfcinB17-25 and 
LfcinB17-24 reinforces the importance of the R residue at the C-terminal position, 
whereas the differences between LfcinB17-31 and LfcinB17-32 support the role of C-
terminal P residue in enhancing inhibition.85 Interestingly several LF-derived 
sequences identified from a hydrolysate obtained either with pepsin 
(LNNSRAP)82 or produced by the yeast Kluyveromyces marxianus (DPYKLRP, 
PYKLRP, YKLRP and GILRP)80 also have a C-terminal P residue although 
different inhibitory potencies were found (IC50 values from 10.2 to 105.3 µM). The 
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yeast proteolytic system produced the set of sequences DPYKLRP, PYKLRP and 
YKLRP differing in the amino acidic residue at the N-terminal end, and together 
with the sequence GILRP share the C-terminal tripeptide LRP. Remarkably LRP, 
which can be found in three different regions of LF sequence, was pointed out as 
the sequence responsible of the in silico high ACE-inhibitory activity of different 
peptide sequences in LF, and in accordance with our results, an IC50 value of 
0.27 µM was described for the tripeptide.13 Including the peptides KLRP and LRP 
in the study, sequence-inhibitory potency relationships could be established and 
suggested that N-terminal elongations to the sequence LRP decreased in vitro
inhibitory potency.80 Moreover elongations at the C-terminal end of the tripeptide 
also provoked a decrease of inhibitory potency since an IC50 value of 4.14 µM 
was previously described for the sequence LRPVAA.78
However, as described for many food-derived ACE-inhibitory peptides, in 
vitro inhibitory potencies of LF-derived peptides might not result in higher 
antihypertensive effects as can be seen in Table 1. Despite the in vitro ACE-
inhibitory activity showed by LfcinB-derived peptides, in the in vivo experiments 
only LfcinB20-25, with the higher IC50 value of all of them, showed a moderate 
antihypertensive effect (-16.7 ± 3.2 mm Hg) in SHR, that was 7.7 % reduction 
from baseline SBP.81 Peptides derived from other LF regions showed similar 
behavior on in vivo assays (from -13.2 mm Hg to -26.8 mm Hg) than that expected 
from in vitro potencies (from 0.35 µM to 105.3 µM). Although the IC50 values of 
LF-derived peptides were by far higher than that of ACE-inhibitory drug captopril 
(0.022 µM),89 in the conditions tested, oral administration of DPYKLRP, LRP and 
LIWKL resulted in a significant decrease in SBP (13.4% reduction from baseline 
for DPYKLRP and LRP; 12.1% reduction for LIWKL) similar to that of captopril 
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(14% reduction). As occurred after captopril administration, the antihypertensive 
effect of these three LF-derived sequences remained significant for up to 24 h 
post-administration. Moreover, the BP-lowering effect after intravenous injection 
in SHR of LRPVAA was about 210% of that induced by captopril.78 These results 
are also in agreement with previously reported antihypertensive effects of other 
food-derived peptides, which might possess higher in vivo effects than expected 
from in vitro inhibitory potencies probably due to their higher affinity to target 
tissues and their slower elimination.90 Since ACE is a peptidase with broad 
substrate specificity, degradation of bioactive peptides by ACE has been argued 
to explain the lack of antihypertensive effect in SHR of some in vitro inhibitory 
peptides. This led to classify ACE-inhibitory peptides into three groups: inhibitor 
type, of which IC50 values are not affected by pre-incubation with ACE; the 
substrate type, peptides that are hydrolyzed by ACE to give peptides with a 
weaker activity, and the prodrug-type inhibitor, peptides that are converted to true 
inhibitors by ACE or other gastrointestinal proteases. Ideally, only peptides 
belonging to the inhibitor or prodrug-type might exert antihypertensive activities 
after oral administration in SHR.91
The lack of correlation between the in vitro ACE-inhibitory activity and the 
in vivo antihypertensive effect was also observed when characterizing the 
antihypertensive effects of complex LF hydrolysates (LFH) obtained either by 
enzymatic hydrolysis with different proteases such as pepsin, proteinase K and 
trypsin82, 92 or by proteolytic dairy yeasts growing in LF as sole nitrogen source.93
LFH were subjected to ultrafiltration through 3 kDa cut-off membranes and the 
resulting permeates (LFH < 3 kDa) inhibited ACE with IC50 values from 1.3 µg/mL 
(proteinase K LFH) to 140.2 µg/mL (Kluyveromyces lactis LFH) (see Table 1). 
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ACE inhibition by LFHs was comparable to previously reported values of other 
food protein-derived hydrolysates.6, 94, 95 The antihypertensive effects of the LFHs 
in SHR did not correlate with their in vitro ACE effects. Remarkably trypsin LFH 
one of the most potent LFHs did not produce significant changes in SBP of SHR. 
By contrast yeast LFHs produced a significant BP-lowering effect after oral 
administration to SHR, although the effect was transient and less pronounced 
than the effect produced by administration of captopril. Pepsin LFH significantly 
reduced SBP and maintained the effect up to 24 h post-administration as 
observed for captopril.  
Ex vivo inhibitory effects on ACE-dependent vasoconstriction. One step 
further in understanding the mechanisms underlying the antihypertensive effects 
of ACE-inhibitory peptides is to gain functional evidence for the ACE-inhibitory 
effects of peptides in vascular tissue. This can be assessed by ex vivo assays 
using isolated arteries since local formation of Ang II from Ang I by ACE present 
in the arterial wall is necessary for induction of contraction by Ang I, which lacks 
vasoactive effects by itself.96, 97
LF-derived peptides and hydrolysates showed different inhibitory effects 
on Ang I-induced contractions (Table 1). Peptide pre-incubation induced 
significant inhibitions when compared to the control with the exception of LfcinB19-
25, WQ and LNNSRAP. Regarding hydrolysates, pepsin LFH but not proteinase 
K LFH inhibited ACE-dependent vasoconstriction at a concentration of 100 
µg/mL.92 Non-hydrolysed LF did not provoke any inhibitory effect on Ang I-
induced vasoconstriction while a non-ultrafiltered pepsin LFH only achieved such 
effect at a concentration of 1350 µg/mL98 pointing out that the ex vivo ACE-
inhibitory effect may be mainly attributable to peptide components with molecular 
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masses lower than 3 kDa. Representative recordings of ex vivo inhibitory effect 
on ACE-dependent vasoconstriction in rabbit isolated arteries by the well-known 
ACE inhibitor captopril and LfcinB17-31 can be seen in Figure 3. Reduction of Ang 
I-induced vasoconstriction of thoracic aorta preparations after treatment with the 
casein derived ACE-inhibitory and antihypertensive peptide MKP at 100 µg/mL 
has been recently described.99 Interestingly radiolabeled 14C-MKP orally 
administered to SHR was absorbed and moved into plasma, suggesting that its 
ACE-inhibitory activity might contribute to induce the antihypertensive effect in 
vivo.99. In our ex vivo assays, LF-derived peptides showed inhibition of 
vasoconstriction at lower concentrations (20 µM in the assay corresponding to 
11-42 µg/mL) than that described for MKP, suggesting the higher ex vivo ACE-
inhibitory potency of LF-derived peptides. 
As a general trend there was no correlation between in vitro potency and 
effect on ACE-dependent vasoconstriction of LF-derived peptides (see Table 1); 
for instance, LfcinB19-25 with a high in vitro inhibitory potency (IC50 2.3 ± 0.2 µM) 
did not show any effect on ACE-dependent vasoconstriction in contrast to 
LfcinB20-25, LfcinB17-31 and LfcinB17-22 that had in vitro IC50 values approximately 
10-fold higher.81 Also, RPYL and LIWKL showed similar inhibitory effects on 
ACE-dependent vasoconstriction (14% and 22% response reduction over the 
control conditions, respectively) despite their 100-fold different in vitro potencies 
(IC50 values of 56.5 and 0.47 µM, respectively). Although this discrepancy 
deserves further research, a methodological detail could at least in part account 
for it, since in vitro tests were carried out with porcine ACE, while rabbit arteries 
were used in ex vivo tests, and variations in the inhibition profiles of ACE from 
different species have been reported.100 Moreover, the fact that the 
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antihypertensive sequences WQ and LNNSRAP as well as proteinase K LFH did 
not show any inhibitory effect on ACE-dependent vasoconstriction suggests a 
mechanism for the in vivo antihypertensive action other than inhibition of ACE-
related vasoactive effects. By contrast, the antihypertensive effect of pepsin LFH, 
LfcinB20-25, RPYL and LIWKL might be due to in vivo ACE inhibition and 
subsequent reduction of Ang I-induced vascular tone. 
In vivo ACE inhibition. As part of the homeostatic mechanism responsible for 
the maintenance of normal BP and electrolyte balance, ACE is a key component 
of the RAS which main function is to cleave Ang I to Ang II and degrade bradykinin 
(Figure 1). Therefore, in vivo ACE-inhibitory effect can be assessed by measuring 
tissue membrane-anchored or soluble circulating ACE activities, and confirmed 
by measuring circulating levels of Ang II. 101
In vivo effect of pepsin LFH on ACE activity was assessed after long-term 
oral administration to SHR.102 Pepsin LFH attenuated and even reversed 
progression of hypertension. Results showed that serum ACE activity was 
reduced in pepsin LFH-treated SHR. Moreover inhibition of ACE was confirmed 
by the reduction in Ang II level as well as in the level of aldosterone, the adrenal 
endocrine component downstream Ang II in the renin-angiotensin axis,20 thus 
supporting ACE inhibition as an in vivo mechanism for the antihypertensive effect 
of pepsin LFH. In addition, our results also showed that ACE inhibition induced a 
compensatory rise of plasma renin activity which is due to the reduction of 
negative feedback by Ang II.103 This renin increase further supports ACE 
inhibition as the antihypertensive mechanism of pepsin LFH. 
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Similarly, the acute antihypertensive effects of LF-derived peptides 
DPYKLRP and LRP might also be attributed to in vivo ACE inhibition because of 
reductions in circulating ACE activity and Ang II levels after either DPYKLRP or 
LRP single-intake. By contrast to that observed in pepsin LFH treatment, plasma 
aldosterone level of SHR was not significantly affected by any of the single-dose 
peptide treatments.80 A reduction of circulating Ang II levels accompanied the BP-
lowering effects in SHR after long-term oral administration of the egg-derived 
ACE-inhibitory peptides IQW and LKP, suggesting RAS regulation through ACE 
inhibition.104 The egg-derived tripeptides decreased plasma Ang II levels by 
approximately 50 % after long-term treatment, but ACE activity was not 
measured. In our short-term in vivo experiments with the LF-derived sequence 
DPYKLRP, the maximum reductions both in ACE activity (48 %) and in Ang II 
level (27 %) were achieved at 1 h post administration. Moreover these effects 
were similar to those provoked by captopril.80
Another approach to assess in vivo ACE inhibition is the use of Ang I-
induced hypertension rat models, which suitability has been shown for 
captopril105 and diverse non-drug natural products.106-108 Regarding LF-derived 
peptides, to investigate their in vivo antihypertensive mechanism, the BP-
lowering effects of RPYL and DPYKLRP in Wistar rats subjected to Ang I-induced 
hypertension were assessed. After inducing hypertension by subcutaneous 
infusion of Ang I, LF-derived peptides were orally administered, and both 
sequences, RPYL and DPYKLRP, were able to reverse Ang I-elicited 
hypertension.109 Moreover, like in SHR (see Table 1), the magnitude and duration 
of the antihypertensive effect were higher for DPYKLRP than for RPYL on Ang I-
induced hypertension. Thus in vivo ACE inhibition is involved in the 
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antihypertensive effects of LF-derived peptides like RPYL and DPYKLRP, as 
suggested by two different in vivo experimental approaches.80, 109
5.1.2. Inhibition of angiotensin II receptor-mediated vasoconstriction 
Inhibition of RAS at the level of AT1 receptors is also a target for hypertension 
treatment (Figure 1). This effect is achieved by angiotensin receptor blocker 
(ARB) drugs, e.g. valsartan, because of their ability to bind to AT1 receptors, 
thereby inhibiting vasoconstriction and other cellular actions of Ang II.110, 111
Functional ex vivo assays using isolated arteries are also useful to study 
the inhibitory effects on Ang II-induced, AT1 receptor mediated vasoconstriction. 
The inhibitory effects of LF-derived peptides on Ang II-induced vasoconstriction 
have been assessed.112 Peptides LfcinB20-25, LIWKL and RPYL, pepsin LFH and 
the ARB valsartan produced significant inhibition of Ang II-induced 
vasoconstriction whereas captopril was included as negative control (Table 2). 
The degree of inhibition ranged from 21 % response reduction over the control 
conditions for the weakest LfcinB20-25 to 44 % response reduction for the 
strongest RPYL, the concentration-dependent inhibitory effect (20-200 µM) of 
which was also shown. Thus, these results point to inhibition of Ang II-induced 
vasoconstriction as a potential mechanism also contributing along with ACE 
inhibition to the antihypertensive effect of LF-derived peptides.112 Moreover, the 
AT1 receptor-blocking mechanism for the inhibitory effect of RPYL on Ang II-
induced vasoconstriction was also supported by the fact that the peptide induced 
significant inhibition of [125I]-(Sar1, Ile8)-Ang II specific binding to both human and 
rabbit AT1 receptors in a ligand-binding assay.112 However, when assessing the 
BP-lowering effect of RPYL in Wistar rats subjected to Ang II-induced 
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hypertension, no inhibition of the vasopressor effect caused by Ang II was 
observed,109 as would be expected from results found in ex vivo and binding 
assays.112 Interestingly, DPYKLRP produced a modest reversion of Ang II-
elicited hypertension. Thus, in vivo ACE inhibition is involved in the 
antihypertensive effects of LF-derived peptides like RPYL and DPYKLRP, while 
inhibition of AT1 receptor-mediated vasoconstriction plays a less relevant role.109
5.2. Effects on the endothelin system 
The ET system has also been targeted for hypertension drug treatment by means 
of ECE inhibition or ET receptor antagonism (Figure 2). Selective ECE inhibitors 
have been tested in preclinical rat models of hypertension,113, 114 and ET receptor 
antagonists have been approved for pulmonary hypertension treatment and are 
under clinical development for systemic hypertension treatment.22
Since present strategies in the search of novel classes of antihypertensive 
drugs include the development of single compounds capable of simultaneously 
inhibiting more than one receptor or enzymatic activity involved in hypertension 
pathophysiology,115 we developed a method to assay the effects of bioactive 
peptides on the ET system, which combines an in vitro test for the inhibitory effect 
on ECE activity and a functional ex vivo test for the inhibitory effect on ECE-
dependent big ET-1-induced vasoconstriction and ECE-independent ET-1-
induced vasoconstriction in rabbit isolated arteries.116
Significant inhibition of ECE activity, using the natural ECE substrate big 
ET-1 in order to obtain more functionally relevant results, were observed for 
seven LfcinB-derived peptides116 and two sequences, GILRPY and REPYFGY, 
identified in a proteinase K LFH.92 Also two antihypertensive hydrolysates, pepsin 
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LFH and proteinase K LFH, showed significant ECE-inhibitory effects in a 
concentration-dependent manner.92 With respect to ex vivo functional assays of 
ECE inhibition in vascular tissue, we checked that big ET-1 induces ECE-
dependent vasoconstriction, as supported by the inhibition of big ET-1-induced, 
but not ET-1-induced contractions with the ECE inhibitor phosphoramidon.116
Regarding LfcinB-derived peptides, six of them inhibited big ET-1-induced, ECE-
dependent vasoconstriction with good correlation with the in vitro inhibitory 
effects,116 while two LF-hydrolysates induced inhibition when compared to control 
vasoconstriction. However, in contrast to in vitro assays of ECE inhibitory effect, 
pepsin LFH induced higher inhibition of vasoconstriction than that produced by 
the proteinase K LFH.92 Table 3 summarizes the inhibitory effects of LF-derived 
peptides and hydrolysates on ECE activity and ECE-dependent vasoconstriction. 
Of note, ex vivo functional assays for ECE-independent ET-1-induced 
vasoconstriction showed that LF-derived peptides do not act on downstream ETA
receptors or intracellular signal transduction mechanisms leading to 
vasoconstriction.112, 116
Taken into account the effects of LfcinB-derived peptides and LFHs on 
ACE and ECE inhibition (see Tables 1 and 3), five of the LfcinB-derived peptides 
were dual vasopeptidase (ACE/ECE) inhibitors with anti-vasoconstrictor effects. 
Results suggest dual ACE and ECE inhibition as mechanisms involved in the 
antihypertensive effect observed in SHR after pepsin LFH administration, and 
that ECE inhibition seems to be the mechanism involved in the moderate 
antihypertensive effect of proteinase K LFH. In vivo effects of LF-derived peptides 
on the ET system require further research. 
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5.3 Effects on other blood pressure regulating pathways 
Nowadays high throughput techniques offer a powerful approach for 
understanding the molecular basis of bioactive compounds. Regarding 
antihypertensive peptides, for which several molecular targets have been 
highlighted, global approaches represent a feasible strategy for revealing the 
action of these peptides through distinct BP regulating pathways. DNA microarray 
technology was applied for the analysis of changes in gene expression in aorta 
of SHR after repeated administration of casein-derived VPP and IPP.117 Changes 
in gene expression were mild and the most marked differences were found in the 
expression of genes associated with vascular function, such as the endothelial 
NO synthase (eNOS) gene, the connexin 40 (gap junction 40) gene and the NF-
B (nuclear factor kappa B subunit) gene. For the arachidonic acid system, the 
cyclooxigenase (COX-1) gene showed a slight increase in expression after VPP 
and IPP administration, and related to cytokine production, the PPAR 
(peroxisome proliferator activator receptor, gamma) gene showed significantly 
lower expression after the VPP and IPP treatment. There were no significant 
changes in the expression resulting from the intake of VPP and IPP, for genes 
associated with the RAS or with the blood coagulation system. Recently, the 
same technology was used to determine the molecular mechanism of the 
antihypertensive effect of milk fermented by Lactobacillus helveticus.118 It was 
found that hypertension-associated genes differentially expressed in the left 
ventricle of SHR were related to NO synthesis, cell proliferation, ET binding and 
blood clot breakdown. Specifically, regulation of eNOS, PPAR and ETA receptor 
genes could be responsible for the antihypertensive response provoked by 
fermented milk treatment. 
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Regarding LF-derived antihypertensive peptides, the effects of pepsin LFH 
on the expression of a panel of genes related to hypertension were evaluated by 
RT-PCR in human umbilical vein endothelial cells (HUVEC).119 Pepsin LFH 
treatment significantly affected the expression of genes encoding proteins 
involved in the NO pathway such as NO synthase trafficking (NOSTRIN) and 
soluble guanylate cyclase 1 3 subunit (GUCY1A3). NOSTRIN is a protein which 
modulates subcellular distribution of eNOS and thus NO release. Its 
overexpression promotes the translocation of eNOS from the plasma membrane 
to intracellular vesicles, with a concomitant reduction in eNOS enzyme activity 
and inhibition of NO synthesis.120 Conversely, decreased NOSTRIN expression 
also influences eNOS subcellular localization and contributes to increase NO 
levels in endothelial cells.121 We found that NOSTRIN expression was 
significantly downregulated after LFH treatment for 24 h and that this result was 
consistent with a reduced protein expression detected by immunoblot analysis 
and an increased NO production. In addition, our results also showed upregulated 
expression of soluble guanylate cyclase GC (GUCY1), the physiological target of 
NO122 and presumably the most relevant molecular target for NO-releasing drugs 
in human cardiovascular therapy.123 Furthermore, expression of the 
PTGS2/COX-2 gene encoding prostaglandin-endoperoxide synthase 2, a key 
component of prostaglandin synthesis, was significantly increased following 
pepsin LFH treatment in HUVEC.119 In healthy humans, COX-2 generates mainly 
prostacyclin, a potent vasodilator and platelet inhibitor.124 Moreover, it has been 
described that ACE inhibitors increase expression of COX-2 and prostacyclin 
levels in different experimental models 125 thus suggesting that COX-2 induction, 
like that provoked by LFH, may potentiate vasodilator activity. 
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Despite inhibition of ACE activity by pepsin LFH was shown in cultured 
HUVEC supernatants, no effect on ACE mRNA levels was observed,119 in 
agreement to that found in aorta of SHR after administration of VPP and IPP.117
Despite ECE has been shown as a molecular target for pepsin LFH,92 we did not 
find significant changes in ECE relative mRNA level or in expression of other 
genes associated with the ET system.119 Time-course effect of pepsin LFH in 
HUVEC on mRNA levels of genes associated with RAS and ET system are 
necessary to discard any regulation at the mRNA level at shorter exposure times. 
Although studies assessing the antihypertensive mechanisms of action of 
food protein-derived peptides by means of global approaches are still scarce, 
they point to different molecular targets in the NO and prostaglandin pathways. 
Moreover these studies reveal the complexity of effects exerted by 
antihypertensive LF-derived peptides opening avenues for the better 
understanding of their BP-lowering effects. Undoubtedly the application of these 
techniques to different in vitro and in vivo models will considerably extend the 
current evidence regarding LF-derived antihypertensive peptides and 
hypertension management. 
6. Conclusions and perspectives 
Data reported here demonstrate the potential application of LF-derived peptides 
released from different regions of the protein in the control of hypertension. These 
bioactive peptides can be obtained by enzymatic hydrolysis, but also using GRAS 
(Generally Recognized As Safe) proteolytic dairy yeasts. Different experimental 
approaches, including in vitro, ex vivo and in vivo assays point out the RAS 
pathway, mainly ACE but also AT1 receptors, as a target for LF-derived 
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antihypertensive peptides. Renin inhibition, recently highlighted as a potential 
mechanism for other food-derived antihypertensive peptides,9 has not been 
directly assessed for LF-derived sequences but remarkably an increase of 
plasma renin activity in SHR after long-term treatment with pepsin LFH as a 
compensatory effect of ACE inhibition was observed. Further research is needed 
to establish the role of renin inhibition in the antihypertensive effect of LF-derived 
peptides. Results suggest that ECE inhibition but not ETA receptor blocking 
mechanism might also contribute to the in vivo antihypertensive effect of LF-
derived peptides some of which might act as dual ACE/ECE vasopeptidase 
inhibitors. Hence, involvement of the ET system in the BP-lowering effects merits 
future studies. Finally, the HUVEC in vitro model showed that pepsin LFH was 
able to increase NO production and modify the expression of hypertension related 
genes, suggesting NOSTRIN as a target for LF-derived peptides. The potential 
contribution of prostaglandins was also suggested. Figure 4 summarizes the 
mechanisms by which LF-derived peptides might exert antihypertensive effects. 
 All together these studies identify several molecular targets for LF-derived 
peptides other than ACE inhibition and highlight the multiple mechanisms 
underlying BP-lowering effects, reinforcing the great value of LF as an effective 
source of multifunctional antihypertensive peptides. Nevertheless clinical trials 
are mandatory to demonstrate the antihypertensive effects of LF-derived 
peptides already observed in SHR and to obtain further evidence of the 
participation of such peptides in different BP regulatory pathways. Finally, a last 
but not least important issue is related to the bioavailability properties of LF-
derived antihypertensive peptides. Certainly identification of the peptide active 
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fragment able to reach the molecular target in the organism as well as the 
evaluation of absorption, distribution, metabolism and excretion are essential. 
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Figure captions 
Fig. 1 Renin-angiotensin and kallikrein-kinin systems, from peptide precursors to 
receptors involved in blood pressure regulation. Sites of action of inhibitory 
antihypertensive drugs are depicted by the symbol . ACE, angiotensin I-
converting enzyme; AT1, angiotensin type 1 receptor; B2, kinin type 2 receptor; 
NO, nitric oxide. 
Fig. 2 Endothelin system, from peptide precursors to receptors involved in blood 
pressure regulation. Sites of action of inhibitory antihypertensive drugs are 
depicted by the symbol . ET, endothelin; ECE, endothelin converting enzyme; 
ETA, endothelin type A receptor; ETB, endothelin type B receptor. 
Fig. 3 Ex vivo inhibitory effect of the lactoferrin-derived peptide LfcinB17-31 on 
ACE-dependent vasoconstriction. Rabbit carotid artery segments are subjected 
to isometric tension recording in an organ bath, and representative recordings 
are shown. Top: Angiotensin I (Ang I; 1 M) induces phasic, transient contraction. 
Preincubation with the ACE inhibitor drug captopril (1 M) completely abolishes 
Ang I-induced contraction. This inhibition is reversible after captopril wash-out, 
thus supporting ACE-dependence of Ang I-induced contraction. Bottom: LfcinB17-
31 (20 M), inhibits Ang I-induced, ACE-dependent vasoconstriction. Adapted 
from Centeno et al., 2006.79
Fig. 4 Antihypertensive mechanisms of lactoferrin-derived peptides: the effects 
on the renin-angiotensin system, the endothelin system and pathway for nitric 
oxide (NO) production promote reduction of vascular tone and subsequent blood 
pressure downregulation. Inhibition sites are depicted by the symbol , whereas 
stimulation sites are depicted by the symbol . ACE, angiotensin I-converting 
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enzyme; AT1, angiotensin type 1 receptor; ECE, endothelin converting enzyme; 
ET, endothelin; ETA, endothelin type A receptor; NOSTRIN, NO synthase 
trafficking. 
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Table 1 ACE-inhibitory potency, inhibition of ACE-dependent vasoconstriction and oral antihypertensive effects of lactoferrin (LF)-
derived peptides and hydrolysates 






LfcinB17-32 FKCRRWQWRMKKLGAP 11.0 ± 1.5 20 n.s. 81 
LfcinB17-31 FKCRRWQWRMKKLGA 25.5 ± 2.3 21 n.s. 79,81 
LfcinB20-25       RRWQWR 32.0 ± 4.9 30 -16.7 ± 3.2 81 
LfcinB19-25     CRRWQWR 2.3 ± 0.1 n.s. n.s. 81 
LfcinB18-25   KCRRWQWR 5.8 ± 0.2 25 n.s. 81 
LfcinB17-25 FKCRRWQWR 2.9 ± 0.6 26 n.s. 81 
LfcinB17-24 FKCRRWQW 10.5 ± 0.6 18 n.s. 81 
LfcinB17-22 FKCRRW 26.7 ± 1.9 28 n.s. 81 
LfcinB21-23          RWQ n.d. n.d. n.s. 81 
LfcinB22-23            WQ n.d. n.s. -11.4 ± 2.7 81 
LF-derived 
f(266-270) LIWKL 0.47 ± 0.01 22 -25.3 ± 3.5  82 
f(133-136) RPYL 56.5 ± 1.9 14 -18.9 ± 2.3 82 
f(232-238) LNNSRAP 105.3 ± 6.4  n.s. -15.3 ± 3.7 82 
f(70-76) DPYKLRP 30.5 ± 1.4  n.d. -26.8 ± 2.4 80 
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f(71-76)   PYKLRP 10.2 ± 1.2 n.d. -22.3 ± 0.9 80 
f(72-76)    YKLRP 16.5 ± 0.7 n.d. -21.1 ± 1.6 80 
f(73-76)      KLRP 91.6 ± 4.0 n.d. -13.2 ± 0.9 80 
f(74-76), f(132-134), f(427-429)        LRP 0.35 ± 0.03 n.d. -26.8 ± 1.3 80 
f(130-134) GILRP 90.7 ± 5.0 n.d. -20.5 ± 2.9 80 
LF hydrolysates 
Pepsin LFH  14.3 ± 3.3 29 -15.9 ± 3.6 82 
Proteinase K LFH  1.3 ± 0.1 n.s. -19 ± 7 92 
Trypsin LFH  6.9 ± 0.2 n.d. n.s. 92 
Debaryomyces hansenii LFH  89.6 ± 3.7 n.d. -18 ± 2 93 
Kluyveromyces lactis LFH  140.2 ± 9.2 n.d. -12 ± 1 93 
Kluyveromyces marxianus LFH  50.2 ± 2.7 n.d. -24 ± 1 93 
aIC50 values are given in µM (peptides) or µg/mL (LF hydrolysates) units. 
bInhibition of ACE-dependent vasoconstriction expressed as the percentage with respect to control. Peptides were assayed at 20 µM 
and hydrolysates at 100 µg/mL. 
cMaximum decrease in SBP after oral doses of 10 mg/kg (peptides) or 200 mg/kg (LF hydrolysates). 
n.s. not significant; n.d. not determined. 
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Table 2 Inhibitory effects of lactoferrin-derived peptides, captopril and valsartan 
on angiotensin II-induced vasoconstriction 
Compound Inhibition of vasoconstriction (%)a
LfcinB20-25 (20 µM) 21 
LIWKL (20 µM) 30 
RPYL (20 µM) 44 
RPYL (200 µM) 80 
Pepsin LFH (100 µg/mL) 25 
Captopril (0.1 µM) n.s. 
Valsartan (10 nM) 69 
Valsartan (0.1 µM) 88 
aInhibition of ang II-dependent vasoconstriction expressed as the 
percentage with respect to control. 
n.s. not significant 
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Table 3 Inhibitory effects of lactoferrin (LF)-derived peptides and hydrolysates on 
endothelin-converting enzyme (ECE) activity and ECE-dependent 
vasoconstriction 
Peptidea ECE inhibition 
(%)b




LfcinB17-32 81 54.0 116 
LfcinB17-31 82 54.0 116 
LfcinB19-25 67 66.4 116 
LfcinB18-25 42 43.8 116 
LfcinB17-25 86 62.0 116 
LfcinB17-24 38 n.s. 116 
LfcinB17-22 38 54.7 116 
LF-derived 
GILRPY 13 n.d. 92 
REPYFGY 23 n.d. 92 
LF hydrolysates 
Pepsin LFH 92 30.8 92 
Proteinase K LFH 31 21.2 92 
aPeptides were assayed at 30 µM and hydrolysates at 100 µg/mL. 
bPercent of ECE activity inhibition with respect to a control without peptide or 
hydrolysate. 
cInhibition of ECE-dependent vasoconstriction expressed as the percentage with 
respect to that of control. 
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